Literature DB >> 11443481

Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases.

M M Chren1, R J Lasek, A P Sahay, L P Sands.   

Abstract

BACKGROUND: An accurate, sensitive, but brief quality-of-life outcomes measure is needed for studies of dermatologic care.
OBJECTIVE: To construct a single-page version of Skindex (a dermatologic quality-of-life instrument) that would have two new features compared with the current 29-item version: (1) fewer items to which a majority of patients choose the same response, and (2) measurement of bother rather than frequency of patient experiences.
METHODS: Random samples of patients waiting for dermatology appointments in clinics of Veterans Affairs hospitals and in private dermatology practices completed questionnaires; 692 patients responded to the parent instrument and 541 additional patients responded to the brief version. Reproducibility, internal consistency reliability, validity, and responsiveness of the brief version of Skindex were determined.
RESULTS: For 16 items of the current 29-item version (55%), more than 50% of patients responded "Never." After an explicit process of item analysis and elimination, a single-page 16-item version was composed that asks patients about bother from their experiences; responses are reported as three scales, Symptoms, Emotions, and Functioning. For 6 items of the 16-item version (38%), more than 50% of patients responded "Never." Scale scores were reproducible after 72 hours (r = 0.88-0.90) and were internally reliable (Cronbach's alpha = 0.86-0.93). The instrument demonstrated both content and construct validity: Most patients' responses to an open-ended question about their skin disease was addressed by the items; patients with inflammatory dermatoses had higher scores than those with isolated lesions; and in an exploratory principal axes factor analysis with an oblique rotation, 74% of the common variance was explained by three factors that correlated with the a priori scales. Mean scale scores stayed the same or changed in the expected direction in patients who reported that their skin was the same or had improved.
CONCLUSION: This brief single-page version of Skindex accurately and sensitively measures how much patients are bothered by their skin conditions.

Entities:  

Mesh:

Year:  2001        PMID: 11443481     DOI: 10.1007/BF02737863

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  82 in total

1.  Adaptation of a Runyankore version of Skindex-16 for oral administration in Mbarara, Uganda.

Authors:  Ser Ling Chua; Toby Maurer; Mary-Margaret Chren
Journal:  Int J Dermatol       Date:  2011-10       Impact factor: 2.736

Review 2.  The Skindex instruments to measure the effects of skin disease on quality of life.

Authors:  Mary-Margaret Chren
Journal:  Dermatol Clin       Date:  2011-12-20       Impact factor: 3.478

3.  FACE-Q Skin Cancer Module for measuring patient-reported outcomes following facial skin cancer surgery.

Authors:  E H Lee; A F Klassen; S J Cano; K S Nehal; A L Pusic
Journal:  Br J Dermatol       Date:  2018-05-23       Impact factor: 9.302

4.  The effect of melasma on self-esteem: A pilot study.

Authors:  J Jiang; O Akinseye; A Tovar-Garza; A G Pandya
Journal:  Int J Womens Dermatol       Date:  2017-12-08

Review 5.  A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies.

Authors:  Alexandre Chan; Michael C Cameron; Benjamin Garden; Christine B Boers-Doets; Katja Schindler; Joel B Epstein; Jennifer Choi; Laura Beamer; Eric Roeland; Elvio G Russi; René-Jean Bensadoun; Yi Ling Teo; Raymond J Chan; Vivianne Shih; Jane Bryce; Judith Raber-Durlacher; Peter Arne Gerber; César O Freytes; Bernardo Rapoport; Nicole LeBoeuf; Vincent Sibaud; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2015-01-07       Impact factor: 3.603

6.  Acute skin toxicity-related, out-of-pocket expenses in patients with breast cancer treated with external beam radiotherapy: a descriptive, exploratory study.

Authors:  Julie B Schnur; Joshua Graff Zivin; David M K Mattson; Sheryl Green; Lina H Jandorf; A Gabriella Wernicke; Guy H Montgomery
Journal:  Support Care Cancer       Date:  2012-03-18       Impact factor: 3.603

7.  [Quality of life in dermatology. From measurement to practical implementation].

Authors:  K Müller; S Karrer; C Apfelbacher; C Blome; M Berneburg; M Koller
Journal:  Hautarzt       Date:  2015-04       Impact factor: 0.751

8.  Effect of store and forward teledermatology on quality of life: a randomized controlled trial.

Authors:  John D Whited; Erin M Warshaw; Karen E Edison; Kush Kapur; Lizy Thottapurathu; Srihari Raju; Bethany Cook; Holly Engasser; Samantha Pullen; Patricia Parks; Tom Sindowski; Danuta Motyka; Rodney Brown; Thomas E Moritz; Santanu K Datta; Mary-Margaret Chren; Lucinda Marty; Domenic J Reda
Journal:  JAMA Dermatol       Date:  2013-05       Impact factor: 10.282

9.  The Vulvovaginal Symptoms Questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women.

Authors:  Elisabeth A Erekson; Sallis O Yip; Terri S Wedderburn; Deanna K Martin; Fang-Yong Li; Jennifer N Choi; Kimberly S Kenton; Terri R Fried
Journal:  Menopause       Date:  2013-09       Impact factor: 2.953

Review 10.  Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.

Authors:  Lawrence F Eichenfield; Wynnis L Tom; Sarah L Chamlin; Steven R Feldman; Jon M Hanifin; Eric L Simpson; Timothy G Berger; James N Bergman; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Alfons Krol; David J Margolis; Amy S Paller; Kathryn Schwarzenberger; Robert A Silverman; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury
Journal:  J Am Acad Dermatol       Date:  2013-11-27       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.